Coherus Oncology Receives Nasdaq Deficiency Notice for Stock Price

Summary

Coherus Oncology Inc. received a deficiency notice from NASDAQ because its stock price closed below $1.00 for 30 consecutive trading days. The company must maintain a closing price of at least $1.00 for 10 consecutive trading days by December 29, 2025, to regain compliance. If unsuccessful, it may seek a 180-day extension by transferring to the NASDAQ Capital Market and consider a reverse stock split. Coherus is actively monitoring the situation and evaluating options.Reuters

Impact Analysis

First-Order Effects: The deficiency notice directly impacts Coherus Oncology Inc. by threatening its NASDAQ listing status, which could lead to decreased investor confidence and stock price volatility. The company must act swiftly to regain compliance, possibly through a reverse stock split, which may temporarily stabilize the stock price but could also signal financial instability. Second-Order Effects: Peer companies in the same industry may observe increased caution from investors, potentially leading to wider scrutiny of stock performance in the biotech sector. Investment Opportunities: Short-term investors might explore options strategies such as buying puts to hedge against further declines or seeking opportunities if the company announces positive corrective measures.Reuters